Spruce Biosciences, Inc. (SPRB)
OTCMKTS · Delayed Price · Currency is USD
0.0606
-0.0053 (-8.04%)
Jun 5, 2025, 3:12 PM EDT

Spruce Biosciences Company Description

Spruce Biosciences, Inc. is a biopharmaceutical company focused on developing and commercializing novel therapies for neurological disorders.

The company develops TA-ERT, a fusion protein comprised of recombinant human alpha-N-acetylglucosaminidase, which is an enzyme replacement therapy for patients with Sanfilippo Syndrome Type B.

It also develops Tildacerfont for treating a highly debilitating mental disorder characterized by depressed mood with cognitive-affective and somatic changes, including anhedonia, weight alterations, and altered sleeping patterns.

In addition, the company develops SPR202 for the treatment of Congenital Adrenal Hyperplasia (CAH), a chronic and potentially life-threatening rare disease with no cure, and SPR204, a monoclonal antibody antagonist for Post-Bariatric Hypoglycemia.

The company has a license agreement with Eli Lilly and Company to research, develop, and commercialize various pharmaceutical compounds.

It also has a collaboration and license agreement with Kaken Pharmaceutical Co. Ltd. to develop, manufacture, and commercialize Tildacerfont for the treatment of CAH in Japan.

Spruce Biosciences, Inc. was incorporated in 2014 and is headquartered in South San Francisco, California.

Spruce Biosciences, Inc.
Spruce Biosciences logo
Country United States
Founded 2014
Industry Biotechnology
Sector Healthcare
Employees 21
CEO Javier Szwarcberg

Contact Details

Address:
611 Gateway Boulevard
South San Francisco, Delaware 94080
United States
Phone 415 655 4168
Website sprucebio.com

Stock Details

Ticker Symbol SPRB
Exchange OTCMKTS
Stock Type Common Stock
Fiscal Year January - December
Reporting Currency USD
ISIN Number US85209E1091
SIC Code 2836

Key Executives

Name Position
Dr. Javier Szwarcberg M.D., M.P.H. Chief Executive Officer and Director
Michael G. Grey Executive Chairman
Samir M. Gharib CPA, M.B.A. President and Chief Financial Officer
Dr. Kirk Ways M.D., Ph.D. Chief Medical Officer and Director